Staphylococcal superantigen-like proteins (SSL) show no superantigenic activity but have recently been considered to act as immune suppressors. It was previously reported that SSL5 bound to Pselectin glycoprotein ligand-1 (PSGL-1) and matrix metalloproteinase (MMP)-9, leading to inhibition of leukocyte adhesion and invasion. These interactions were suggested to depend on sialic acidcontaining glycans of MMP-9, but the roles of sialic acids in the interaction between SSL5 and MMP-9 are still controversial. In the present study, we prepared recombinant glutathione S-transferasetagged SSL5 (GST-SSL5) and analyzed its binding capacity to MMP-9 by pull-down assay after various modifications of its carbohydrate moieties. We observed that GST-SSL5 specifically bound to MMP-9 from a human monocytic leukemia cell line (THP-1 cells) and inhibited its enzymatic activity in a concentration-dependent manner. After MMP-9 was treated with neuraminidase, its binding activity towards GST-SSL5 was markedly decreased. Furthermore, recombinant MMP-9 produced by sialic acid-deficient Lec2 mutant cells showed much lower affinity for SSL5 than that produced by wild-type CHO-K1 cells. Treatment of MMP-9 with PNGase F to remove N-glycan resulted in no significant change in the GST-SSL5/MMP-9 interaction. In contrast, the binding of GST-SSL5 to MMP-9 secreted from THP-1 cells cultured in the presence of an inhibitor for the biosynthesis of O-glycan (benzylGalNAc) was weaker than the binding of GST-SSL5 to MMP-9 secreted from untreated cells. These results strongly suggest the importance of the sialic acid-containing O-glycans of MMP-9 for the interaction of MMP-9 with GST-SSL5. members; SSL1-SSL11 are encoded in the staphylococcal pathogenicity island 2 (SaPI2) in a conserved order among most strains, and SSL12-SSL14 are encoded in the immune evasion cluster (5). Several studies, including ours, have indicated the relevance of SSL to immune evasion; SSL3 as a TLR2 antagonist (6, 7), SSL7 as an inhibitor for IgA-mediated opsonization and complement activation (8), and SSL10 as a chemokine receptor antagonist and a complement activation inhibitor (9-11).
members; SSL1-SSL11 are encoded in the staphylococcal pathogenicity island 2 (SaPI2) in a conserved order among most strains, and SSL12-SSL14 are encoded in the immune evasion cluster (5) . Several studies, including ours, have indicated the relevance of SSL to immune evasion; SSL3 as a TLR2 antagonist (6, 7) , SSL7 as an inhibitor for IgA-mediated opsonization and complement activation (8) , and SSL10 as a chemokine receptor antagonist and a complement activation inhibitor (9) (10) (11) .
We previously showed that one of the target molecules for SSL5 was MMP-9 (gelatinase B) (12) . Recombinant SSL5 specifically bound to MMP-9 from human neutrophils and inhibited its enzymatic activity. SSL5 was also reported to bind to PSGL-1 expressed on leukocytes, including neutrophils and monocytes, and to inhibit the interaction between P-selectin and PSGL-1 (13) . P-selectin is a cell adhesion molecule that is expressed on the surface of activated endothelial cells and platelets, and the P-selectin/PSGL-1 interaction mediates the initial step of leukocyte recruitment to inflammatory tissues and hemorrhagic sites. Therefore, SSL5 inhibits two distinct steps of leukocyte migration and is thought to facilitate S. aureus infection. P-selectin recognizes a carbohydrate structure specifically expressed on PSGL-1 (known as sialyl Lewis X), and SSL5 is thought to competitively interfere with the Pselectin/PSGL-1 interaction by binding to the same carbohydrate structure (14) . SSL5 is also known to interact with platelet glycoprotein (GP) Iba, GPVI and integrin aIIbb3 in a sialic acid-dependent manner (15, 16) . These results strongly suggest that sialic acidcontaining glycans play a crucial role in the binding of SSL5 to its target molecules. However, a recent report showed that the treatment of MMP-9 with neuraminidase did not alter the binding of SSL5 to MMP-9, although the SSL5/PSGL-1 interaction was abrogated by neuraminidase treatment (17) . Thus, the involvement of sialic acid residues of MMP-9 in the SSL5/MMP-9 interaction is still controversial. In the present study, therefore, we evaluated the roles of sialic acid-containing glycans by using recombinant SSL5 and MMP-9 with modified carbohydrate chains.
MATERIALS AND METHODS

Reagents
Isopropyl-b-D-thiogalactopyranoside (IPTG), lysozyme, glutathione (reduced form), 2-ME, kanamycin sulfate, PMA, Triton X-100, and CBB R-250 were purchased from Wako Pure Chemical Industries (Osaka, Japan). Brij 35 (polyoxyethylene lauryl ether) and 4-aminophenylmercuric acetate (APMA) were purchased from Sigma-Aldrich (St Louis, MO, USA). Benzyl-GalNAc was purchased from Merck Millipore (Bedford, MA, USA). Glutathione-agarose and gelatin Sepharose 4B were products of Thermo Fisher Scientific (Waltham, MA, USA) and GE Healthcare (Piscataway, NJ, USA), respectively. RPMI 1640 medium and ASF 104 serum-free medium were purchased from Sigma-Aldrich and Ajinomoto (Tokyo, Japan), respectively. FBS was supplied by Biosera (Boussens, France). Blasticidin-S hydrochloride was purchased from Invitrogen (Carlsbad, CA, USA).
Antibodies and lectins
A monoclonal antibody against GST was prepared in our laboratory. Anti-human MMP-9 antibody was purchased from R&D Systems (Minneapolis, MN, USA). HRP-conjugated goat antibody to mouse IgG and HRPconjugated rabbit antibody to goat IgG were purchased from Kirkegaard & Perry Laboratories (Burlingame, CA, USA). Biotin-conjugated SSA and HRP-conjugated LCA were purchased from Cosmo Bio Co., Ltd (Tokyo, Japan). Biotin-conjugated VVA-B 4 was prepared in our laboratory (18) . HRP-conjugated streptavidin was purchased from BioLegend (San Diego, CA, USA).
Cell culture
THP-1 (a human monocytic leukemia cell line), CHO-K1 (Chinese hamster ovary cells), and Lec2 mutant cells (19) were grown in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2-ME (50 mM), and kanamycin sulfate (100 mg/mL) at 37°C under humidified 5% CO 2 .
Preparation of recombinant GST-SSL5
The SSL5 gene (ssl5) was amplified by PCR using genomic DNA of S. aureus (ATTC 27733) as a template. The primers used for PCR were 5 0 -GGG GAT CCC CGA ACA TAA AGC AAA ATA T-3 0 (forward primer with a BamHI recognition site [underlined] ) and 5 0 -GGG CGG CCG CTT ATC TAA TGT TGG CTT C-3 0 (reverse primer with a NotI recognition site [underlined] ). PCR was conducted using KAPATaq EXTra (KAPA Biosystems, Boston, MA, USA) under the following conditions: 95°C, 1 min; 55°C, 1 min; 72°C, 1 min; 35 cycles. After sequencing analysis to verify the correct sequence, SSL5 DNA was cloned into pGEX-5X-1 (GE Healthcare). The GST-SSL5 fusion protein (GST-SSL5) was expressed in Escherichia coli (SoluBL21; Genlantis, San Diego, CA, USA) in the presence of 0.2 mM IPTG for 16 hr at 25°C. The bacteria were suspended in sonication buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA) and incubated with lysozyme (1.0 mg/mL) for 20 min on ice. The suspension was sonicated and centrifuged at 18,800 Â g for 30 min. The supernatant was then incubated with glutathione-agarose overnight at 4°C. The GST-SSL5 bound to glutathione-agarose was eluted with 40 mM glutathione (reduced form) in 50 mM Tris-HCl buffer (pH 8.0) and applied to a PD-10 column (GE Healthcare) to replace the buffer with PBS. Purity of recombinant GST-SSL5 was checked by SDS-PAGE (10% gel) and successive western blotting using anti-GST antibody.
Purification of MMP-9
MMP-9 was purified from a human monocytic leukemia cell line (THP-1 cells) essentially as described previously (12) . Briefly, THP-1 cells (1 Â 10 6 cells/mL) were stimulated with 5 nM PMA in ASF 104 serum-free medium at 37°C for 48 hr. After centrifugation at 1,500 rpm for 5 min, the culture supernatant was mixed with gelatin-Sepharose 4B and incubated overnight at 4°C with gentle agitation. The bound MMP-9 was eluted with elution buffer (5% DMSO, 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl 2 ) and immediately applied to a PD-10 column to replace the buffer with TNC buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl 2 , pH 7.5).
Pull-down assay
Purified recombinant GST-SSL5 or GST (15 mg) was bound to glutathione-agarose at room temperature for 1 hr. The GST-SSL5 or GST-loaded glutathione-agarose was incubated with conditioned medium of PMAstimulated THP-1 cells at 4°C for 1 hr with gentle agitation. After glutathione-agarose beads were washed with 0.25% Brij 35 in PBS, proteins bound to the beads were eluted with SDS sample buffer (50 mM Tris-HCl, 1% SDS, 5% glycerol, 0.01% bromophenol blue, pH 6.8) and analyzed by gelatin zymography and western blotting using anti-GST and anti-MMP-9 antibodies.
Purified MMP-9 (10 mg) was bound to gelatinSepharose 4B at room temperature for 1 hr. The MMP-9-loaded gelatin-Sepharose 4B was incubated with purified GST-SSL5 or GST (15 mg) at 4°C for 1 hr with gentle agitation. After gelatin-Sepharose 4B beads were washed with 0.25% Brij 35 in PBS, proteins bound to the beads were eluted with SDS sample buffer and analyzed by western blotting using anti-GST and anti-MMP-9 antibodies.
Gelatin zymography
Gelatin zymography was performed essentially as described previously (20) . Briefly, samples containing metalloproteinases were separated by SDS-PAGE (7.5% gel containing 0.5% gelatin), and the gel was washed three times with 1% Triton X-100 for 20 min, and subsequently with incubation buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl 2 , 1 mM ZnCl 2 , pH 7.5) for 16 hr. The gel was then stained with CBB and destained with 30% methanol/10% acetic acid.
Measurement of MMP-9 activity
MMP-9 activity was measured using fluorogenic peptide as a substrate (12, 21) . Purified MMP-9 (9.6 nM) was activated by 1 mM APMA at 37°C for 3 hr and treated with GST-SSL5 or GST (0-200 nM) at room temperature for 2 hr. The mixture was incubated with a fluorescencequenching substrate for matrix metalloproteinases, MOCAc-Pro-Leu-Gly-Leu-A 2 pr(Dnp)-Ala-Arg-NH 2 (1 mM) (Peptide Institute, Osaka, Japan), in reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl 2 , 0.1% Brij 35) (2 mL) at 25°C, and fluorescence (Ex: 328 nm; Em: 393 nm) was measured with a fluorescence spectrophotometer (Model F-4010; Hitachi, Tokyo, Japan). Experiments were performed in triplicate, and statistical data analysis was conducted using the Student's t-test.
Neuraminidase and PNGase F treatments
To remove sialic acid residues from MMP-9, purified MMP-9 specimen (15 mg) was incubated with neuraminidase from Clostridium perfringens (New England Biolabs, Ipswich, MA, USA) (1,250 units/mL) in 50 mM sodium acetate buffer (pH 5.5) containing 5 mM CaCl 2 at 37°C for 3 hr.
To remove N-glycans from MMP-9, the purified MMP-9 specimen (15 mg) was incubated with PNGase F (New England Biolabs) (12,500 units/mL) in 50 mM sodium phosphate buffer (pH 6.0) at 37°C for 3 hr.
Benzyl-GalNAc treatment
THP-1 cells (1 Â 10 6 cells/mL) were cultured in ASF 104 medium containing 2 mM benzyl-GalNAc, an inhitor for O-glycan biosynthesis (22) , and 5 nM PMA at 37°C for 48 hr. The culture supernatant was recovered and analyzed for MMP-9 by gelatin zymography, western blotting and lectin blotting.
Introduction of MMP-9 cDNA into CHO-K1 and Lec2 mutant cells
The MMP-9 cDNA was amplified by PCR using a set of primers: 5 0 -agt gtg gtg gaa ttc ATG AGC CTC TGG CAG CCC-3 0 (forward primer, the vector sequence is in lower case) and 5 0 -ata tct gca gaa ttc CTA GTC CTC AGG GCA CTG-3 0 (reverse primer, the vector sequence is in lower case) (23) . The PCR was conducted using primeSTAR MAX DNA polymerase (Takara Bio, Shiga, Japan) under the following conditions: 98°C, 10 s; 55°C, 15 s; 72°C, 15 s; 40 cycles. The resultant PCR product was cloned into the EcoRI restriction site of pcDNA6/V5-HisA (Invitrogen) by using an in-fusion HD cloning kit (Takara Bio). The plasmid construct (pcDNA6-hMMP-9) was introduced into CHO-K1 or Lec2 mutant cells by electroporation. CHO-K1 or Lec2 cells (7.0 Â 10 6 cells/0.7 mL) in PBS were mixed with plasmid DNA (20 mg), and the mixture was subjected to electroporation (a single pulse of 250 V at a capacitance of 950 mF) in a 0.4 cm-electroporation cuvette (Gene Pulser Xcell TM ; Bio-Rad, Hercules, CA, USA). After the cell suspension was diluted with RPMI 1640 medium (10 mL) supplemented with 10% FBS, the cells were cultured at 37°C for 24 hr and selected for the stable clones with blasticidin-S (20 mg/mL).
RESULTS
GST-SSL5 binds to MMP-9 from THP-1 cells and inhibits its enzymatic activity
We previously examined the SSL5/MMP-9 interaction by using His-tagged SSL5 (12) . Because MMP possess metal ions such as zinc ions in their active sites, we prepared GST-tagged SSL5 in this study to eliminate the possibility that His-tagged SSL5 affects enzymatic activity by chelating metal ions of the enzyme. When recombinant GST-SSL5 and control GST purified from E. coli were analyzed by SDS-PAGE, each recombinant protein gave a single band in the expected molecular weight range ($48 kDa for GST-SSL5 and $25 kDa for control GST) after CBB staining or western blotting (Fig. 1) . We next conducted a pull-down assay using immobilized GST-SSL5 and GST. The conditioned medium of PMA-stimulated THP-1 cells was incubated with GST-SSL5-agarose or control GST-agarose, and the bound proteins were analyzed by gelatin zymography. As shown in Figure 2a , the fraction bound to GST-SSL5-agarose gave two bands, proMMP-9 monomer ($92 kDa) and proMMP-9 multimer ($250 kDa) (24), whereas no band was detected from the fraction bound to GST-agarose. The proMMP-9 monomer band ($92 kDa) was confirmed by western blotting using anti-MMP-9 antibody. We then carried out a pull-down assay, in reverse, using MMP-9-loaded gelatin-Sepharose 4B and soluble GST-SSL5 or GST. When the proteins coprecipitated with immobilized MMP-9 were analyzed by western blotting using anti-GST antibody, GST-SSL5, but not control GST, was detected (Fig. 2b) . These results indicate that GST-SSL5 specifically binds to MMP-9 secreted from THP-1 cells.
We examined the effects of GST-SSL5 on the enzymatic activity of MMP-9 by using a fluorogenic peptide substrate. As shown in Figure 3 , GST-SSL5 inhibited MMP-9 activity in a concentration-dependent way, whereas GST did not significantly affect the enzymatic activity. The inhibition by GST-SSL5 (200 nM) was estimated to be $73%.
Binding of GST-SSL5 to MMP is mediated by sialic acid residues
To examine the role of sialic acid-containing glycans of MMP-9, we treated MMP-9 with neuraminidase and subjected neuraminidase-treated or -untreated MMP-9 to pull-down assay. We first analyzed both samples by lectin blotting with a sialic acid-specific lectin, SSA. The neuraminidase-treated MMP-9 was found to interact with the lectin more weakly than the intact specimen (Fig. 4a) , although antigenicity and enzymatic activity were not significantly affected as assessed by western blotting and zymographic analyses. Pull-down assay clearly showed that GST-SSL5-agarose failed to coprecipitate neuraminidase-treated MMP-9 (Fig. 4b) .
Lec2 mutant cells are deficient in the biosynthesis of sialic acid-containing glycans as a result of a mutation in the CMP-sialic acid transporter (19) . We isolated recombinant MMP-9 from the conditioned media of Lec2 mutant and wild-type CHO-K1 cells after cDNA transfection. The pull-down assay using GST-SSL5-agaros e in combination with zymography or western blotting showed that immobilized SSL5 bound to MMP-9 derived from CHO-K1 cells but did not bind to MMP-9 from Lec2 mutant cells (Fig. 5) . These results indicate that the sialic acids of MMP-9 are crucial for its interaction with GST-SSL5.
Fig. 1. Electrophoretic analysis of recombinant GST-tagged SSL5 (GST-SSL5).
Two sets of recombinant GST-SSL5 and the control GST were separated by SDS-PAGE (12.5%). One gel was stained with CBB (left), and the other was subjected to western blotting analysis using anti-GST antibody (right).
O-Glycans of MMP-9 are involved in its interaction with GST-SSL5
Human neutrophil MMP-9 contains both N-glycans and O-glycans; N-and O-glycans comprise $15% and $85%, respectively, of the total carbohydrates in this glycoprotein (25) . We next examined which type of glycan is crucial for the interaction with GST-SSL5. A purified MMP-9 specimen was treated with PNGase F to remove N-glycans and subjected to a pull-down assay. Western blotting using anti-MMP-9 antibody and zymographic analyses showed that PNGase F-treated MMP-9 migrated slightly faster than the intact MMP-9 in SDS-PAGE (Fig. 6a) , probably as a result of the removal of N-glycans. The removal of N-glycans was also suggested by the decreased reactivity of PNGase F-treated MMP-9 with LCA (a lectin specific for complex-type N-glycans) on lectin blotting analysis (Fig. 6a) . The pull-down assay showed that both the intact and de-N-glycosylated MMP-9 were similarly coprecipitated with GST-SSL5-agarose (Fig. 6b) .
We next prepared MMP-9 with modified O-glycosylation from THP-1 cells cultured in the presence of benzyl-GalNAc. Benzyl-GalNAc inhibits elongation of O-linked carbohydrate chains in cellular glycoprotein biosynthesis, resulting in an increase of short carbohydrate chains such as Tn-antigen (GalNAca-Thr/Ser) (22) . MMP-9 in the conditioned medium of THP-1 cells cultured with benzyl-GalNAc was applied to lectin blotting using VVA-B 4 (a GalNAcspecific lectin) (18, 26) . As shown in Figure 7a , MMP-9 Fig. 3 . Inhibition of MMP-9 activity by recombinant GST-SSL5. APMA-activated MMP-9 (9.6 nM) from THP-1 cells was incubated with a fluorogenic peptide substrate in the presence of GST-SSL5 or GST (0-200 nM) at 25°C for 10 min. Increase in fluorescence was measured (Ex: 328 nm; Em: 393 nm) with a fluorescence spectrophotometer. Experiments were carried out in triplicate, and the data are presented as the mean AE SEM.
Ã P < 0.005.
Fig. 4.
Effects of neuraminidase treatment of MMP-9 on its binding to GST-SSL5. (a) MMP-9 was treated with neuraminidase (1250 units/mL) at 37°C for 3 hr. Neuraminidase-treated (Neu) and untreated (À) samples were analyzed by SDS-PAGE (7.5% gel) followed by western blotting using anti-MMP-9 antibody (WB), lectin blotting using biotinylated SSA (LB), and gelatin zymography (Zymography). (b) Neuraminidase-treated (Neu) and untreated (À) samples were subjected to pull-down assay using GST-SSL5-agarose as described in Materials and methods. The bound materials were analyzed by western blotting using anti-MMP-9 antibody (upper panel) and anti-GST antibody (lower panel).
Fig. 2.
Binding of GST-SSL5 to MMP-9 from THP-1 cells as assessed by pull-down assay. (a) Conditioned medium of THP-1 cells was incubated with GST-SSL5-agarose or control GST-agarose, and bound proteins were analyzed by SDS-PAGE (10%) followed by gelatin zymography (upper panel). The same samples were also analyzed by western blotting using anti-MMP-9 antibody (lower panel). (b) Recombinant GST-SSL5 or control GST was incubated with MMP-9-loaded gelatin-Sepharose 4B, and bound proteins were analyzed by SDS-PAGE (12.5%) followed by western blotting using anti-GST antibody (upper panel) or anti-MMP-9 antibody (lower panel).
from benzyl-GalNAc-treated THP-1 cells gave a more intense band on lectin blotting analysis as compared with that from untreated THP-1 cells. The pull-down assay with GST-SSL5-agarose showed that MMP-9 from benzyl-GalNAc-treated THP-1 cells possessed weaker reactivity with GST-SSL5 (Fig. 7b) , suggesting that O-gycans of MMP-9 play a crucial role in its binding to GST-SSL5. Because the previous study showed that benzyl-GalNAc treatments of human cancer cell lines at the same concentration (2 mM) as used in the present study inhibited O-glycan elongation by 70-80% as assessed by the [ 3 H]glucosamine labeling method (27), we also estimate that 20-30% sialic acid residues of O-glycans remain in MMP-9 from THP-1 cells, resulting in weak reactivity toward GST-SSL5.
DISCUSSION
In the present study, we investigated the role of sialic acid-containing glycans in the interaction between MMP-9 from THP-1 cells and recombinant SSL5. Our results can be summarized as follows: (i) treatment of MMP-9 with neuraminidase reduced the binding to GST-SSL5; (ii) MMP-9 derived from sialic acid-deficient mutant Lec2 cells possessed lower affinity for GST-SSL5 as compared to that from wild-type CHO-K1 cells; (iii) treatment of MMP-9 with PNGase F did not alter its binding capacity to GST-SSL5; and (iv) MMP-9 secreted from THP-1 cells treated with the O-glycosylation inhibitor benzyl-GalNAc showed lower affinity for GST-SSL5. Based on these results, we conclude that sialic acid-containing O-glycans of MMP-9 play a major role in the interaction of MMP-9 with GST-SSL5. However, this conclusion is somewhat inconsistent with a recent study by Koymans and coworkers (17) in which the interaction between SSL5 and MMP-9 was not significantly influenced by neuraminidase treatment. The reason for the apparent discrepancy is not clear at present, but it might be related to differences in the conditions for the reactions used in these studies. Although it is unclear whether the neuraminidase treatment effectively cleaved sialic acid linkages in MMP-9 under the conditions used in their Samples treated with or without PNGase F were subjected to pull-down assay using GST-SSL5-agarose as described in Materials and methods. The bound materials were analyzed by western blotting using anti-MMP-9 antibody (upper panel) and anti-GST antibody (lower panel).
Fig. 5.
Interaction between SSL5 and MMP-9 from sialic aciddeficient Lec2 cells. Conditioned media of MMP-9-transfected Lec2 mutant or CHO-K1 cells were subjected to pull-down assay using GST-SSL5-agarose. The bound proteins as well as the whole samples input into the assay were analyzed by gelatin zymography (upper panel) and western blotting using anti-MMP-9 antibody (lower panel). Samples of the pull-down assay were also analyzed by western blotting using anti-GST antibody.
study, sialic acid residues were suggested to contribute, at least in part, to the SSL5/MMP-9 interaction because a slight decrease in the binding of neuraminidase-treated MMP-9 to SSL5 was also observed in their study (17) . Other studies have reported that SSL5 is bound by leukocyte PSGL-1 (13, 14) and platelet glycoproteins (GPIba, GPVI, and integrin aIIbb3) (15, 16) in a sialic acid-dependent way. Thus, SSL5 has affinity for various sialylated glycoproteins of hematopoietic cells, including leukocytes and platelets, but the binding to the target molecules appears to be rather selective, suggesting that SSL5 might recognize not only sialylated glycans but also polypeptide structures of glycoproteins.
In structural studies on human neutrophil MMP-9 (25, 28) , O-glycans were estimated to comprise approximately 85% of the total carbohydrates and to consist mainly of type 2 cores with Galb1-4GlcNAc (Nacetyllactosamine) extensions with or without sialic acid residues. These studies also indicated that clustered O-glycans were attached to a type V collagen-like domain consisting of $56 amino acid residues, which is located in the center of the MMP-9 molecule. SSL5 probably binds to this heavily O-glycosylated region. This is consistent with the observation that MMP-2 (gelatinase A) lacking this domain was not bound by SSL5. The region abundant in O-glycans is adjacent to the active site of MMP-9 (28), and the binding of SSL5 to this O-glycosylated region may influence conformation of the active site of the enzyme. Human galectin-8, a member of the galectin family of lectins, is known to bind to human neutrophil proMMP-9 and accelerate MMP-3-mediated processing of proMMP-9 (29) . The detailed mechanism underlying this observation is unclear, but this is another example of the possible modulation of MMP-9 activity through the binding of carbohydrate-recognizing molecules.
Leukocyte PSGL-1 and platelet GPIba have also been identified as target molecules for SSL5 (13) (14) (15) (16) . Both PSGL-1 and GPIba are heavily O-glycosylated mucin-like glycoproteins (30, 31) and possess a domain with clustered sialic acid-containing glycans, which is a common feature shared by MMP-9. Structures of the major carbohydrate chains of these three glycoproteins consisted of type 2 cores modified by N-acetyllactosamine units and/or sialic acid and fucose residues. One possibility is that a cluster of sialylated O-glycans is recognized by SSL5 as a target epitope.
Our previous study showed that transmigration of neutrophils across Matrigel basement membranes or gelatin-coated membranes was suppressed in the presence of recombinant SSL5, probably as a result of its inhibitory effect on MMP-9 (12) . SSL5 also inhibits the interaction of PSGL-1 with P-selectin expressed on activated endothelial cells, and impairs tethering and rolling of leukocytes on the activated endothelium, thereby interfering with leukocyte extravasation. Thus, SSL5 is considered to synergistically inhibit leukocyteendothelium adhesion and matrix-degrading enzyme, and consequently facilitates S. aureus infection by escaping from host immunity. The present study may provide insight into the molecular mechanisms underlying the immune evasion of S. aureus.
